Based on the team's discovery that an enzyme called CD38, implicated in aging metabolism, is elevated in scleroderma and underlies fibrosis, they created an antibody engineered to selectively ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

Conversion of mP to ADPR using a standard curve demonstrates that ADPR formation is linear with enzyme. At 12 pM CD38, about 1.5 μM ADPR was produced, which was 10% substrate conversion from 15 ...

“Targeting the CD38 enzyme is a very innovative concept that could be the next pharmacological approach for fibrosis treatment,” said Varga, also the Frederick Huetwell Professor.

CD38 is an enzyme with NAD-depleting and intracellular signaling activity expressed on the cell surface, in intracellular compartments and in mitochondria, and is linked to inflammatory and autoimmune ...

Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Y-mAbs Therapeutics, Inc. announced the presentation of preclinical ...

To uncover the molecular mechanisms regulating ovarian NAD+ loss, first the researchers began by adding another piece of the puzzle: CD38, an enzyme known to be one of the main culprits in ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...